Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Carbamazepine-induced tics.

R Kurlan1, J Kersun, J Behr

  • 1Department of Neurology, University of Rochester School of Medicine and Dentistry, NY 14642.

Clinical Neuropharmacology
|August 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mechanical Properties of Percutaneous Transluminal Coronary Angioplasty Balloon Catheters: A Bench Study.

Annals of biomedical engineering·2026
Same author

Diagnosis and Treatment of Hypersensitivity Pneumonitis: S2k Guideline of the German Respiratory Society and the German Society for Allergology and Clinical Immunology.

Respiration; international review of thoracic diseases·2025
Same author

Design of percutaneous transluminal coronary angioplasty balloon catheters.

Biomedical engineering online·2023
Same author

Editorial: Blood-Based Biomarkers for Alzheimer's Disease: Are We There Yet?

The journal of prevention of Alzheimer's disease·2022
Same author

Standardizing Electronic Health Record Data on AD/ADRD to Accelerate Health Equity in Prevention, Detection, and Treatment.

The journal of prevention of Alzheimer's disease·2022
Same author

[Linguistic Validation of the "German Lung Fibrosis Health Related Quality of Life Questionnaire"].

Pneumologie (Stuttgart, Germany)·2021
Same journal

Characterization of Propranolol Use and Outcomes in Traumatic Brain Injury at a Level I Trauma Center.

Clinical neuropharmacology·2026
Same journal

Review of Medications That Reduce Neurological Deficits in Patients With Traumatic Brain Injury.

Clinical neuropharmacology·2026
Same journal

Pre-Existing Peak-Dose Dyskinesia and Light Body Weight as Predictors of Ropinirole Patch Dose Modification in Parkinson Disease: A Multicenter Retrospective Study.

Clinical neuropharmacology·2026
Same journal

A Double-blind, Placebo-controlled Study of Lumateperone in the Treatment of Borderline Personality Disorder.

Clinical neuropharmacology·2026
Same journal

Yesterday Once More: Revisiting Catatonia in an Elderly Stroke Patient.

Clinical neuropharmacology·2026
Same journal

Overlapping Hyperosmolar Therapy in Patients With Elevated and Refractory Intracranial Pressure.

Clinical neuropharmacology·2026
See all related articles

Carbamazepine, an anticonvulsant, can rarely induce or worsen tics in patients with existing movement disorders. Underlying basal ganglia issues may predispose individuals to these carbamazepine-induced tics.

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Anticonvulsant medications, including carbamazepine, are widely used for epilepsy and other neurological conditions.
  • Dyskinesias are known potential side effects of anticonvulsant therapy.
  • Carbamazepine-induced tics are infrequently recognized in clinical practice.

Observation:

  • Three patients with pre-existing movement disorders (Huntington's disease, tardive dyskinesia, Tourette's syndrome) were observed.
  • These patients developed new-onset or exacerbated tics following carbamazepine treatment.

Findings:

  • The study confirms that carbamazepine can induce or worsen tic disorders.
  • Basal ganglia neuropathology appears to be a significant predisposing factor for developing carbamazepine-induced tics.
  • The dopaminergic activity of carbamazepine is hypothesized to be the mechanism behind tic induction.

Related Experiment Videos

Implications:

  • Clinicians should consider carbamazepine as a potential cause of new or worsening tics, especially in patients with underlying movement disorders.
  • Further research into the neurobiological mechanisms of carbamazepine-induced tics is warranted.
  • This finding highlights the importance of careful medication monitoring in patients with neurological conditions.